How is Eltrombopag oral route dosed?
The dosage of eltrombopag oral route depends on the individual's medical condition, age, and response to treatment. The usual dose for adults and children 1 year of age and older is 25-50 mg per day, taken with or without food. However, it is important to follow the dosing instructions provided by your doctor. Always consult with your doctor for the correct dosing information and instructions for eltrombopag oral route.
What is the dosage form of Eltrombopag oral route?
The dosage forms of eltrombopag oral route are tablets and powder for suspension.
What medications are contraindication with Eltrombopag oral route?
Please consult with a healthcare professional for guidance on potential contraindications with eltrombopag.
How is Eltrombopag oral route administered?
Eltrombopag oral route is administered by taking the tablets whole, without crushing, breaking, or chewing them. It should be taken without a meal or with a meal low in calcium (50 milligrams or less), and at least 4 hours before or 2 hours after taking antacids, multivitamins containing aluminum, calcium, iron, magnesium, selenium, or zinc, or other products high in calcium. The medicine comes with a Medication Guide and patient instructions, which should be read and followed carefully. Consult your doctor if any questions arise.
What are common precautions when taking Eltrombopag oral route?
Common precautions when taking eltrombopag oral route include:
- Regular progress checks: Your doctor will monitor your progress through regular visits and blood tests.
- Birth control: Use effective birth control to avoid getting pregnant during treatment and for at least 7 days after the last dose. Inform your doctor if you think you have become pregnant while using this medicine.
- Liver problems: Eltrombopag may cause or increase the risk of serious liver problems. Contact your doctor right away if you or your child experience nausea or vomiting, dark urine, light-colored stools, right upper stomach pain, unusual tiredness, or yellow eyes or skin.
- Pediatric use: Safety and efficacy have not been established for treating ITP in children younger than 1 year of age or in children with thrombocytopenia associated with chronic hepatitis C or severe aplastic anemia.
- Geriatric use: Elderly patients may be more likely to have age-related liver problems, which may require caution and adjustments in the dose.
- Breastfeeding: There are no adequate studies to determine the risk associated with using eltrombopag while breastfeeding. Consult your doctor to weigh the potential benefits and risks before taking this medication.
- Drug interactions: Inform your doctor about any other medications or supplements you are taking, as eltrombopag may interact with antacids, multivitamins, and other products high in calcium, among others. Follow your doctor's instructions regarding the timing of these products in relation to eltrombopag. Please consult your healthcare professional for more specific information and advice on precautions related to your individual situation.